Northland Capmk Predicts Stronger Earnings for MiMedx Group

MiMedx Group, Inc. (NASDAQ:MDXG) – Analysts at Northland Capmk boosted their Q1 2025 earnings per share estimates for shares of MiMedx Group in a research report issued to clients and investors on Thursday, February 27th. Northland Capmk analyst C. Byrnes now expects that the company will earn $0.06 per share for the quarter, up from their prior estimate of $0.05. The consensus estimate for MiMedx Group’s current full-year earnings is $0.30 per share. Northland Capmk also issued estimates for MiMedx Group’s Q2 2025 earnings at $0.07 EPS, Q3 2025 earnings at $0.07 EPS, Q4 2025 earnings at $0.08 EPS and FY2026 earnings at $0.38 EPS.

MiMedx Group (NASDAQ:MDXG) last posted its earnings results on Wednesday, February 26th. The company reported $0.07 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.07. The business had revenue of $92.91 million for the quarter, compared to analysts’ expectations of $89.42 million. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%.

A number of other research firms have also recently weighed in on MDXG. StockNews.com cut MiMedx Group from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 8th. Cantor Fitzgerald restated an “overweight” rating and issued a $13.00 price target on shares of MiMedx Group in a research report on Thursday. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $12.40.

MiMedx Group Price Performance

MDXG opened at $8.14 on Friday. The firm has a market cap of $1.20 billion, a PE ratio of 14.80 and a beta of 1.94. The stock has a 50-day moving average price of $8.74 and a 200-day moving average price of $7.68. MiMedx Group has a 1 year low of $5.47 and a 1 year high of $10.14. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.10 and a quick ratio of 3.53.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Blue Trust Inc. acquired a new stake in shares of MiMedx Group during the third quarter worth $30,000. Allspring Global Investments Holdings LLC grew its holdings in MiMedx Group by 1.0% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 183,021 shares of the company’s stock valued at $1,082,000 after purchasing an additional 1,822 shares in the last quarter. Farther Finance Advisors LLC increased its position in shares of MiMedx Group by 88.6% during the third quarter. Farther Finance Advisors LLC now owns 24,599 shares of the company’s stock worth $145,000 after acquiring an additional 11,557 shares during the last quarter. Harbor Capital Advisors Inc. boosted its stake in shares of MiMedx Group by 299.9% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 1,027,738 shares of the company’s stock valued at $6,074,000 after buying an additional 770,744 shares during the last quarter. Finally, Cannon Global Investment Management LLC grew its holdings in MiMedx Group by 47.1% during the 3rd quarter. Cannon Global Investment Management LLC now owns 25,000 shares of the company’s stock worth $148,000 after acquiring an additional 8,000 shares in the last quarter. Institutional investors and hedge funds own 79.15% of the company’s stock.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.